Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Ovarian Cancer Research Foundation announces $2.4 million in new funding
Today, three ovarian cancer research institutions have received significant funding from the Ovarian Cancer Research…
COVID-19 pandemic could have led to 20,000 prostate cancer diagnosis being missed
Prostate cancer diagnoses in 20,000 men could have been missed due to the COVID-19 pandemic,…
Bladder cancer trial SUBDUE-1 shows promising results using a sub-urothelial durvalumab injection
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) SUBDUE-1 trial, featured…
Supporting the optimal management of cancer-related malnutrition and sarcopenia
As many as 150,000 people are expected to be diagnosed with cancer in Australia this year. Of these, 1 in…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.